Group A Streptococcus Brain Abscess in a Patient on Adalimumab Therapy by Carroll, Ryan et al.
Volume 5 Issue 3 Manuscript 1230 
2019 
Group A Streptococcus Brain Abscess in a Patient on Adalimumab 
Therapy 
Ryan Carroll, Ahmad Abu-Hashyeh, James Gainer, Kara Willenburg, and Charles Meadows 
Author Affiliations 
Ryan Carroll (Marshall University, Huntington, West Virginia) 
Ahmad Abu-Hashyeh (Marshall University, Huntington, West Virginia) 
James Gainer (Marshall University, Huntington, West Virginia) 
Kara Willenburg (Marshall University, Huntington, West Virginia) 
Charles Meadows (Marshall University, Huntington, West Virginia) 
Corresponding Author 
Ryan Carroll MD 
Marshall University 
Huntington, West Virginia 
Email: dick23@live.marshall.edu 
Follow this and additional works at: https://mds.marshall.edu/mjm 
 Par  of the Infectious Disease Commons 
Recommended Citation 
Carroll, Ryan; Abu-Hashyeh, Ahmad; Gainer, James; Willenburg, Kara; and Meadows, Charles (2019) "Group A 
Streptococcus Brain Abscess in a Patient on Adalimumab Therapy," Marshall Journal of Medicine: Vol. 5: Iss. 3, 
Article 4. 
DOI: 10.33470/2379-9536.1230 
Available at: https://mds.marshall.edu/mjm/vol5/iss3/4 
DOI: 10.33470/2379-9536.1230 
Author Footnote: Ryan Carroll participated in care of the patient, performed literature review, and 
drafted the final version of the manuscript. Ahmad Abu-Hashyeh performed literature review and 
assisted with drafting the final version of the manuscript. James Gainer participated in care of 
the patient, dratted the case presentation, and assisted with drafting of the final version of the 
manuscript. Kara Willenburg assisted with drafting of the final version of the manuscript. 
Charles Meadows participated in care of the patient and assisted with drafting of the final 
version of the manuscript. 
Open Access | 
Group A streptococcus brain abscess in a patient on adalimumab therapy 
 
Abstract 
 
Brain abscesses represent a group of dangerous infections typically caused by a number of 
classic organisms. Group A streptococcus is a rare cause of brain abscesses and those patients 
that do have this particular condition will typically have a distal source of infection. We present a 
case of patient with a biopsy confirmed group A streptococcal without a distal source of 
infection. His only identifiable risk factor was his adalimumab therapy for ankylosing 
spondylitis. While adalimumab has not been linked to streptococcal infection in the past, it has 
been associated with multiple atypical infections and some of the consequences of its mechanism 
as a tissue necrosis factor alpha inhibitor can theoretically predispose patients to streptococcal 
infection when considered in conjunction with known streptococcal virulence factors. This case 
raises the question of whether the patient’s adalimumab therapy may have contributed to his 
unusual presentation of streptococcal infection and prompts further consideration and study of 
the risks of adalimumab and other similar immunosuppressant monoclonal antibodies. 
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Introduction 
 
Brain abscesses represent a fairly rare infectious process with a significant risk of morbidity and 
mortality. Many brain abscesses have a clear predisposing factor and result from a select group 
of common organisms. We present a case of an abscess caused by Streptococcus pyogenes (S. 
pyogenes), an organism not classically associated with abscess formation and only found as the 
causative agent of brain abscess a handful of times, in a patient without typical predisposing 
factors. Additionally, the previously reported cases have been in pediatric patients and have been 
linked to contiguous spread of infection.1 We examine whether the patient’s long-term 
adalimumab, a tissue necrosis factor alpha (TNF-a) inhibitor therapy, could have contributed to 
his presentation.  
 
Case Report 
 
Our patient is a 62-year-old male with prolonged history of ankylosing spondylitis on 
adalimumab therapy for seven months who presented with a subacute history of progressive 
headaches and right-sided scotomas. He otherwise was asymptomatic and denied fevers or other 
infectious symptoms. Magnetic resonance imaging (MRI) exhibited a 3.2 cm ring-enhancing 
lesion in the left posterior occipital lobe with perilesional edema (Figures 1 and 2). He underwent 
left occipital craniotomy with intraoperative findings significant for purulent material within a 
well-defined capsule and intraoperative cultures grew pansensitive Streptococcus pyogenes. 
Therapy with penicillin G 24 million units given via a daily continuous infusion was initiated. 
The patient was discharged home after eight days in the hospital and continued antibiotic therapy 
for a total duration of eight weeks. At follow-up, he had no residual neurologic deficits or 
complaints.   
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Figure 1. Transverse MRI image showing ring-enhancing lesion 
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Figure 2. Coronal MRI image showing ring-enhancing lesion  
 
 
Discussion 
 
A brain abscess is defined as a pocket of infection within the brain parenchyma and is believed 
to originate from cerebritis which progresses to a well-vascularized capsule.2 Risk factors for its  
development include neurosurgical introduction of pathogens, penetrating trauma, contiguous 
spread from local infections, and hematogenous spread from sources such as endocarditis, 
pneumonia, or soft tissue infections.2,3 However, as many as 40% of brain abscesses have no 
obvious predisposing factor.2 Classical causal relationships between risk factors and certain 
organisms include: dental caries and anaerobic bacteria, trauma with either Staphylococcus 
aureus (S. aureus) or Pseudomonas aeruginosa, and hematogenous spread with S. aureus. 
Notably, abscesses of hematogenous origin tend to be multifocal and in the distribution of the 
middle cerebral artery. Symptoms may include: headache (72-92%), nausea and vomiting (31-
40%), seizure (21-25%), and neurologic deficits including hemiparesis (14-20%).4,5 Given that 
these symptoms are nonspecific, brain imaging and subsequent biopsy are required for diagnosis. 
Initial empiric therapy typically includes a third generation cephalosporin, metronidazole, and 
vancomycin and total duration of therapy depends upon whether complete surgical excision was 
performed and the causative organism.6 Use of steroids and anticonvulsants remains 
controversial.7 
 
S. pyogenes is not a commonly reported abscess-forming pathogen aside from the formation of 
peritonsillar abscesses as a complication of pharyngitis. However, a small number of case reports 
describe S. pyogenes abscesses and postulate on their causative factors. Genetic mutations 
including CovR and RopB, two virulence factor regulators, have been considered and SLO 
mutations, a trigger of neutrophil deactivation and apoptosis, have been identified in S. pyogenes 
cultured from patients with invasive infections.8 Non-steroidal anti-inflammatory drugs 
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(NSAIDs), which our patient had been taking, have also been identified as a potential risk factor 
for invasive S pyogenes infections.9 
 
Adalimumab, a TNF-a inhibitor used in many inflammatory conditions including ankylosing 
spondylitis, Crohn’s disease, and rheumatoid arthritis can predispose users to multiple 
opportunistic infections. The most common opportunistic infections seen with adalimumab 
therapy include fungi, cytomegalovirus, Nocardia, and reactivation of mycobacteria. TNF-a 
promotes neutrophil activation, stimulates macrophage phagocytosis, and increases production of 
interleukin-1 and its blockade hinders these processes. Less predictable effects of TNF-a 
inhibitors have also been documented including apoptosis of monocytes, CD4, and CD8 T 
cells.10 A Cochrane review of adalimumab therapy for ankylosing spondylitis demonstrated its 
efficacy and revealed no statistically different insignificant adverse events.11 Literature review 
yields many reports of the typical opportunistic infections seen with TNF-a inhibitors but no 
reports of unusual streptococcal abscess formation. One case report did note an intra-abdominal 
abscess caused by Kocuria kristinae, a bacterium considered normal skin flora and not known to 
be virulent in humans.12 Given that our patient developed an atypical infection from a common 
organism we question whether some of these immunologic effects of TNF-a inhibitors could 
have predisposed him to his condition. Although S. pyogenes abscesses have not been reported as 
a complication of TNF-a inhibitors, our patient lacked typical risk factors for brain abscess 
formation and also lacked a distal source of S. pyogenes infection. This case report certainly does 
not establish a causal link but does raise questions for further study and analysis of future cases 
to determine if a link exists between TNF-a inhibitors and unusual streptococcal infections.  
 
Conclusion 
 
S. pyogenes has only rarely been reported as the cause of a brain abscess. Our patient lacked 
typical predisposing factors for brain abscess formation including an extracranial site of 
Streptococcal infection but was on an immunosuppressive medication. The possible contribution 
of adalimumab to our patient’s illness must be considered and the implications of a causal 
relationship would be crucial in the evaluation of patients with an intracranial lesion in the 
future. This case report not only provides an interesting example of an uncommon infection, but 
also prompts further consideration and discussion of the risks associated with novel biologic 
agents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
9
Marshall Journal of Medicine, Vol. 5 [2019], Iss. 3, Art. 4
https://mds.marshall.edu/mjm/vol5/iss3/4
DOI: 10.33470/2379-9536.1230
References 
 
1. Capua T, Klivitsky A, Bilavsky E, Askenazi-Hoffkung L, Roth J, Constantini S, Grisaru-Soen G. Group 
A streptococcal brain abscess in the pediatric population: case series and review of the literature. Pediatric 
Infectious Disease Journal. 2018; 7(10):967-970. 
2. Miranda HA, Castellar-Leones SM, Elzain MA, Moscote-Salazar, LR. Brain abscess: current management. 
Journal of Neuroscience in Rural Practice. 2013;4(1):S67-S81. 
3. Nathoo N, Nadvi SS, Narotam PK, Van Dellen JR. Brain abscess: management and outcome analysis of a 
computed tomography era experience with 973 patients. World Neurosurgery. 2011;75:716–726. 
4. Mace SE. Central nervous system infections as a cause of an altered mental status? What is the pathogen 
growing in your central nervous system? Emergency Medicine Clinics of North America. 2010;28:535–
570. 
5. Loeser E, Scheinberg L. Brain abscesses; a review of ninety-nine cases. Neurology. 1957;7:601–609. 
6. Shachor-Meyouhas Y, Bar-Joseph G, Guilburd JN, Lorber A, Hadash A, Kassis I. Brain abscess in 
children-epidemiology, predisposing factors and management in the modern medicine era. Acta 
Paediatrica. 2010;99:1163–1167. 
7. Lu CH, Chang WN, Lui CC. Strategies for the management of bacterial brain abscess. Journal of Clinical 
Neuroscience. 2006;13:979–985. 
8. Kamiya Y, Hasegawa T, Takegami, Y, et al. Primary psoas abscess caused by group A streptococcus in a 
child: case report with microbiologic findings. Journal of Infection and Chemotherapy. 2016; 22(12):811-
814. 
9. Demeslay J, DeBonnecaze G, Vairel B, et al. Possible role of anti-inflammatory drugs in complications of 
pharyngitis. A retrospective analysis of 163 cases. European Annals of Otorhinolaryngology, Head and 
Neck Diseases. 2014;131(5):299-303. 
10. Harris J and Keane J. How tumor necrosis factor blockers interfere with tuberculosis immunity. Clinical 
Experimental Immunology. 2010;161(1):1-9. 
11. Maxwell LJ, Zochling J, Boonen, A et al. TNF-alpha inhibitors for ankylosing spondylitis. The Cochrane 
Database of Systemic Reviews. 2015;18(4):CD005468. 
12. Kolikonda MK, Jayakumar P, Sriramula S, Lippmann S. Kocuria kristinae infection during adalimumab 
treatment. Postgraduate Medicine. 2017;129(2):296-298. 
 
10
Carroll et al.: Streptocococcus Brain Abscess on Adalimumab
Published by Marshall University's Joan C. Edwards School of Medicine, 2019
